Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs in the United States. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate …
| Métrica | RADX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 1.1% | 57.4% | -56.3% |
| Operating Margin | -1050.6% | -34.4% | -1016.3% |
| Net Margin | -1055.3% | -32.5% | -1022.8% |
| FCF Margin | — | -12.6% | — |
| ROE | -89.4% | -39.2% | -50.3% |
| ROA | -44.3% | -30.9% | -13.4% |
| Current Ratio | 2.67 | 2.73 | -0.06 |
| Debt / Equity | — | 0.28 | — |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✗Rentabilidad sobre activos positiva | -44.3% | — |
| ✗Flujo de caja operativo positivo | −$37M | −$23M |
| ✓Rentabilidad sobre activos al alza | -44.3% | -66.6% |
| ✓Caja operativa/activos supera al ROA | -42.4% | ROA -44.3% |
| –Menos deuda a largo plazo | — | — |
| ✓Mejor liquidez (ratio corriente) | 2.67 | 1.30 |
| ✗Sin aumentar el nº de acciones | 2,081M | 386M |
| ✗Margen bruto al alza | 1.1% | 100.0% |
| ✓Rotación de activos al alza | 0.04 | 0.00 |
| Calidad del negocio | FY25 |
|---|---|
| ✗ROCE > 10 % | -53.4% |
| ✓Reinversión (I+D + capex) > 3 % de ventas | 757.3% |
Radiopharm Theranostics Ltd cotiza a 1.03 USD y tiene una capitalización bursátil de $15M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud